Application and Enlightenment of WHO Drug Pricing Method in Medical Insurance Pricing of Proprietary Chinese Medicine in China
Yang Yijiu
Liu Bin
Zhang Haili
Liang Ning
Song Tian
Cao Wenjie
Li Huizhen
Zong Xingyu
Wang Weili
Wang Dingyi
Hu Ziteng
Wang Yanping
Han Sheng
Shi Nannan
Abstract:WHO Guideline on Country Pharmaceutical Pricing Policies,published in 2020,outlines 10 commonly used pricing methods internationally.However,due to the unique composition of costs for traditional Chinese medicine(TCM),directly applying pricing methods designed for chemical and biological drugs may lead to discrepancies.Currently,in China,drug pricing primarily in-volves internal reference pricing,tender negotiation pricing,promoting the use of quality-assured generic and biosimilar drugs,and centralized procurement.It systematically analyzes various pricing methods and identifies their applicability and underlying reasons concerning the pricing of TCMwithin the medical insurance system.The method of value-based pricing and increasing price transparency has advantages for the pricing regulation of traditional Chinese medicine under medical insurance.
Keywords:World Health Organizationpricing of traditional Chinese medicinevalue-based pricingreview
Publication Date:2023-12-05
Online Publishing Date:2025-08-15(First online date of this platform, not the publication date of the document)
Pages:4( 53-56 )
Chinese Health Economics

Chinese Health Economics

ISTICPKUAMI
ISSN:1003-0743
Year, Vol.(Issue):2023,42(12)